Zacks Investment Research·Sep 17, 2026
Best Momentum Stocks to Buy for September 17thMSGM, ASMB and MTG made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 17th, 2026.
Assembly Biosciences' investment thesis is a high-risk, binary bet on clinical pipeline execution, with its financials dominated by lumpy collaboration revenue rather than sustainable commercial traction. The company's recent $305.6M equity base provides a tem...
Price trend, volume and key moving averages
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 13, 2026 | -$0.20+72.4% vs -$0.72 | $13M+55.5% vs $9M |
Q2 2026 May 7, 2026 | -$0.54+26.0% vs -$0.73 | $8M-11.4% vs $9M |
Q2 2026 Mar 19, 2026 | $2.48+586.3% vs -$0.51 | $42M+472.2% vs $7M |
Q4 2025 Nov 10, 2025 | -$0.72-44.0% vs -$0.50 | $11M+44.6% vs $7M |
MSGM, ASMB and MTG made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 17th, 2026.
MOV, MAX, MTG, ASMB and MSGM have been added to the Zacks Rank #1 (Strong Buy) List on September 17th, 2026.
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced senior management will present during the H.C. Wainwright & Co. 28th Annual Global Investment Conference at 8:30 a.m. Eastern Time on September 16, 2026.
COCO, CHEF, ASMB and CDNA stand out as four defensive picks amid volatility induced by rising oil prices and Middle East tensions.
Benchmark ASMB against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Assembly Biosciences, Inc. (ASMB)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $22.54 | $446.68M | -40.98 | 153.52% | -8.47% | -5.1% | — | |
| $64.19 | $9.04B | -5261.48 | 23258.15% | -47.79% | -60.05% | — | |
| $2.56 | $279.54M | -1.27 | — | — | -5.76% | — | |
| $13.07 | $1.1B | -3.87 | — | — | -159.32% | — | |
| $144.74 | $179.7B | 21.35 | 2.39% | -10.64% | -16.35% | — | |
| $735.20 | $75.74B | 17.72 | 0.99% | 27.86% | 18.49% | — |
Assembly Biosciences, Inc. (ASMB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Assembly Biosciences, Inc. (ASMB) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 13, 2026·SEC
Jun 5, 2026·SEC
May 26, 2026·SEC
Get notified when ASMB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Assembly Biosciences, Inc. (ASMB) stock FAQ — growth, dividends, profitability & financials explained
Assembly Biosciences, Inc. (ASMB) reported $74.8M in revenue for fiscal year 2025.
Assembly Biosciences, Inc. (ASMB) grew revenue by 153.5% over the past year. This is strong growth.
Assembly Biosciences, Inc. (ASMB) reported a net loss of $0.0M for fiscal year 2025.
Assembly Biosciences, Inc. (ASMB) has a return on equity (ROE) of -5.1%. Negative ROE indicates the company is unprofitable.
Assembly Biosciences, Inc. (ASMB) had negative free cash flow of $38.6M in fiscal year 2025, likely due to heavy capital investments.
